(Q38758268)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

title

The cost of treating mucormycosis with isavuconazole compared with standard therapy in the UK (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Emma Bagshaw

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Daniel Kuessner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Jan Posthumus

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Cesar Escrig

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Michael Blackney

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Sebastian Marcel Heimann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

13 February 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

Future Microbiology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

515-525

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis

2 April 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Population-based analysis of invasive fungal infections, France, 2001-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Mucormycosis in Iran: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Epidemiology and clinical manifestations of mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Our 2014 approach to mucormycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Mucormycosis treated with posaconazole: review of 96 case reports.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Importance of nondrug costs of intravenous antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

The VITAL study: case control studies are hypothesis-generating - Authors' reply.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French Multicentre Cohort Study (2003-2008)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFMB-2016-0231

21 January 2018

Identifiers

DOI

10.2217/FMB-2016-0231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28191796%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference